BRIGHT MINDS BIOSCIENCES INC (DRUG)
CA10919W4056 - Common Stock
Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy
/PRNewswire/ - Bright Minds Biosciences Inc. (NASDAQ: DRUG), a biotechnology company focused on developing novel therapies for neurological and...
Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy
/CNW/ - Bright Minds Biosciences Inc. (NASDAQ: DRUG), a biotechnology company focused on developing novel therapies for neurological and neuropsychiatric...
DRUG Stock Earnings: Bright Minds Biosciences Reported Results for Q3 2024
Bright Minds Biosciences just reported results for the third quarter of 2024.
DRUG Stock Earnings: Bright Minds Biosciences Reported Results for Q3 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Bright Minds Biosciences (NASDAQ:DRUG) just reported results for the third quar...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to dive into the biggest pre-market stock movers for Monday morning with all of the latest news affecting shares today!
DRUG Stock Earnings: Bright Minds Biosciences Reported Results for Q2 2024
Bright Minds Biosciences just reported results for the second quarter of 2024.
Psychedelic stocks gain after FDA priority review for MDMA therapy (NYSE:CYBN)
The FDA priority review for an MDMA-linked therapy leads to a surge in shares of psychedelic medicine companies such as Mind Medicine (MNMD). Read more here.
Bright Minds Announces Non-Brokered Private Placement Fully Subscribed by Management
/CNW/ - Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ("Bright Minds" or the "Company"), a leading biotechnology company specializing in the...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
We're checking out the biggest pre-market stock movers worth watching on Friday with a dive into all of the latest market stories!
Psilocybin in depression: study shows lasting benefit
Drugmakers focused on psychedelic drugs traded higher on Thursday after peer-reviewed data indicated the lasting benefits of psilocybin in depression. Read more here.
Psilocybin in depression: Study shows lasting benefit (NASDAQ:MNMD)
Drugmakers focused on psychedelic drugs traded higher on Thursday after peer-reviewed data indicated the lasting benefits of psilocybin in depression. Read more here.